GMZ2 vaccine-induced antibody responses, naturally acquired immunity and the incidence of malaria in Burkinabe children
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
GMZ2 vaccine-induced antibody responses, naturally acquired immunity and the incidence of malaria in Burkinabe children. / Dassah, Sylvester; Adu, Bright; Tiendrebeogo, Régis W; Singh, Susheel K; Arthur, Fareed K N; Sirima, Sodiomon B; Theisen, Michael.
In: Frontiers in Immunology, Vol. 13, 899223, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - GMZ2 vaccine-induced antibody responses, naturally acquired immunity and the incidence of malaria in Burkinabe children
AU - Dassah, Sylvester
AU - Adu, Bright
AU - Tiendrebeogo, Régis W
AU - Singh, Susheel K
AU - Arthur, Fareed K N
AU - Sirima, Sodiomon B
AU - Theisen, Michael
N1 - Copyright © 2022 Dassah, Adu, Tiendrebeogo, Singh, Arthur, Sirima and Theisen.
PY - 2022
Y1 - 2022
N2 - GMZ2 is a malaria vaccine candidate evaluated in a phase 2b multi-centre trial. Here we assessed antibody responses and the association of naturally acquired immunity with incidence of malaria in one of the trial sites, Banfora in Burkina Faso. The analysis included 453 (GMZ2 = 230, rabies = 223) children aged 12-60 months old. Children were followed-up for clinical malaria episodes for 12 months after final vaccine administration. Antibody levels against GMZ2 and eleven non-GMZ2 antigens were measured on days 0 and 84 (one month after final vaccine dose). Vaccine efficacy (VE) differed by age group (interaction, (12-35 months compared to 36-60 months), p = 0.0615). During the twelve months of follow-up, VE was 1% (95% confidence interval [CI] -17%, 17%) and 23% ([CI] 3%, 40%) in the 12 - 35 and 36 - 60 months old children, respectively. In the GMZ2 group, day 84 anti-GMZ2 IgG levels were associated with reduced incidence of febrile malaria during the follow up periods of 1-6 months (hazard ratio (HR) = 0.87, 95%CI = (0.77, 0.98)) and 7-12 months (HR = 0.84, 95%CI = (0.71, 0.98)) in the 36-60 months old but not in 12-35 months old children. Multivariate analysis involving day 84 IgG levels to eleven non-vaccine antigens, identified MSP3-K1 and GLURP-R2 to be associated with reduced incidence of malaria during the 12 months of follow up. The inclusion of these antigens might improve GMZ2 vaccine efficacy.
AB - GMZ2 is a malaria vaccine candidate evaluated in a phase 2b multi-centre trial. Here we assessed antibody responses and the association of naturally acquired immunity with incidence of malaria in one of the trial sites, Banfora in Burkina Faso. The analysis included 453 (GMZ2 = 230, rabies = 223) children aged 12-60 months old. Children were followed-up for clinical malaria episodes for 12 months after final vaccine administration. Antibody levels against GMZ2 and eleven non-GMZ2 antigens were measured on days 0 and 84 (one month after final vaccine dose). Vaccine efficacy (VE) differed by age group (interaction, (12-35 months compared to 36-60 months), p = 0.0615). During the twelve months of follow-up, VE was 1% (95% confidence interval [CI] -17%, 17%) and 23% ([CI] 3%, 40%) in the 12 - 35 and 36 - 60 months old children, respectively. In the GMZ2 group, day 84 anti-GMZ2 IgG levels were associated with reduced incidence of febrile malaria during the follow up periods of 1-6 months (hazard ratio (HR) = 0.87, 95%CI = (0.77, 0.98)) and 7-12 months (HR = 0.84, 95%CI = (0.71, 0.98)) in the 36-60 months old but not in 12-35 months old children. Multivariate analysis involving day 84 IgG levels to eleven non-vaccine antigens, identified MSP3-K1 and GLURP-R2 to be associated with reduced incidence of malaria during the 12 months of follow up. The inclusion of these antigens might improve GMZ2 vaccine efficacy.
KW - Antibody Formation
KW - Antigens, Protozoan
KW - Child
KW - Child, Preschool
KW - Humans
KW - Immunoglobulin G
KW - Incidence
KW - Infant
KW - Malaria Vaccines
KW - Malaria, Falciparum/epidemiology
KW - Plasmodium falciparum
U2 - 10.3389/fimmu.2022.899223
DO - 10.3389/fimmu.2022.899223
M3 - Journal article
C2 - 35720297
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 899223
ER -
ID: 311125552